Breaking News

Genmab, Lilly Enter DuoBody Platform Pact

By Kristin Brooks | January 14, 2014

To explore Genmab’s DuoBody for creation of antibodies

Genmab has entered a research collaboration with Eli Lilly and Co. for the use Genmab's DuoBody technology platform to create bispecific antibodies. Lilly will initially evaluate the DuoBody technology platform in house. Financial terms were not disclosed. 
Jan van de Winkel, Ph.D., chief executive officer of Genmab, commented, “Our DuoBody platform continues to attract strong interest from the pharmaceutical industry and we are pleased to enter our fifth partnership for this innovative bispecific antibody technology. Under this new collaboration, Lilly will evaluate the capabilities and strengths of our DuoBody platform and may consider entering a commercial license agreement if the evaluation is successful.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.